GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development
April 30, 2020 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, April 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases...
GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act
March 30, 2020 09:00 ET
|
GeoVax, Inc.
Company Ready to Advance COVID-19 Vaccine Candidates to Animal Efficacy Testing, Manufacturing Scale-Up, and Human Clinical Trials ATLANTA, GA, March 30, 2020 (GLOBE NEWSWIRE) -- via...
GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update
March 25, 2020 09:00 ET
|
GeoVax, Inc.
Recent Pivot to COVID-19 Vaccine Development;Continued Advancements in Other Infectious Disease and Immuno-Oncology Programs ATLANTA, GA, March 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --...
GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program
March 18, 2020 09:00 ET
|
GeoVax, Inc.
Three Vaccine Candidates Completed Nearing Readiness for Animal Efficacy Testing and Human Clinical Trials ATLANTA, GA, March 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs,...
GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program
March 04, 2020 13:00 ET
|
GeoVax, Inc.
Update Given During Presentation at the World Immunotherapy Congress ATLANTA, GA, March 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company...
GeoVax to Present at World Immunotherapy Congress 2020
February 27, 2020 09:00 ET
|
GeoVax, Inc.
Presentation to Include Update on Coronavirus (COVID-19) Vaccine Program ATLANTA, GA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company...
Update: GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
February 06, 2020 11:49 ET
|
GeoVax, Inc.
Company Comments on NIH/NIAID Discontinuance of Sanofi/GSK HVTN 702 Trial ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX) (OTC: GOVXD), a...
GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
February 06, 2020 09:00 ET
|
GeoVax, Inc.
Company Comments on NIH/NIAID Discontinuance of Sanofi/GSK HVTN 702 Trial ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology...
GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine
January 27, 2020 10:18 ET
|
GeoVax, Inc.
ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVXD), a biotechnology company developing human immunotherapies and vaccines against...
GeoVax Announces Reverse Stock Split
January 23, 2020 09:00 ET
|
GeoVax, Inc.
1:2000 Reverse Split Effective January 24, 2020;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, Jan. 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTC: GOVX) today...